instruction stringlengths 34 186 | input stringlengths 2.02k 93.8k | output stringlengths 2 418 | meta_questiontype stringclasses 6
values | meta_inputlicense stringclasses 6
values | meta_pmid stringlengths 8 8 | meta_safetyreportid int64 9.51M 21M | meta_articlepubdate stringlengths 4 10 |
|---|---|---|---|---|---|---|---|
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cardiac failure acute'. | Sipuleucel-T associated inflammatory cardiomyopathy: a case report and observations from a large pharmacovigilance database.
The major cardiovascular (CV) adverse effects observed with sipuleucel-T from large multi-institutional clinical trials included thromboembolic events, myocardial infarction, and congestive heart... | DENOSUMAB, DOCETAXEL, ENZALUTAMIDE, LEUPROLIDE ACETATE, LISINOPRIL, SIPULEUCEL-T | DrugsGivenReaction | CC BY-NC-ND | 33938158 | 20,343,958 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cardiac failure'. | Sipuleucel-T associated inflammatory cardiomyopathy: a case report and observations from a large pharmacovigilance database.
The major cardiovascular (CV) adverse effects observed with sipuleucel-T from large multi-institutional clinical trials included thromboembolic events, myocardial infarction, and congestive heart... | DENOSUMAB, DOCETAXEL, ENZALUTAMIDE, LEUPROLIDE ACETATE, LISINOPRIL, SIPULEUCEL-T | DrugsGivenReaction | CC BY-NC-ND | 33938158 | 20,343,958 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Incorrect route of product administration'. | Sipuleucel-T associated inflammatory cardiomyopathy: a case report and observations from a large pharmacovigilance database.
The major cardiovascular (CV) adverse effects observed with sipuleucel-T from large multi-institutional clinical trials included thromboembolic events, myocardial infarction, and congestive heart... | DENOSUMAB, DOCETAXEL, ENZALUTAMIDE, LEUPROLIDE ACETATE, LISINOPRIL, SIPULEUCEL-T | DrugsGivenReaction | CC BY-NC-ND | 33938158 | 20,343,958 | 2021-08 |
What was the administration route of drug 'DENOSUMAB'? | Sipuleucel-T associated inflammatory cardiomyopathy: a case report and observations from a large pharmacovigilance database.
The major cardiovascular (CV) adverse effects observed with sipuleucel-T from large multi-institutional clinical trials included thromboembolic events, myocardial infarction, and congestive heart... | Subcutaneous | DrugAdministrationRoute | CC BY-NC-ND | 33938158 | 20,343,958 | 2021-08 |
What was the administration route of drug 'LEUPROLIDE ACETATE'? | Sipuleucel-T associated inflammatory cardiomyopathy: a case report and observations from a large pharmacovigilance database.
The major cardiovascular (CV) adverse effects observed with sipuleucel-T from large multi-institutional clinical trials included thromboembolic events, myocardial infarction, and congestive heart... | Intramuscular | DrugAdministrationRoute | CC BY-NC-ND | 33938158 | 20,343,958 | 2021-08 |
What was the dosage of drug 'DOCETAXEL'? | Sipuleucel-T associated inflammatory cardiomyopathy: a case report and observations from a large pharmacovigilance database.
The major cardiovascular (CV) adverse effects observed with sipuleucel-T from large multi-institutional clinical trials included thromboembolic events, myocardial infarction, and congestive heart... | 75 MILLIGRAM PER CUBIC METRE, Q 3 WEEK | DrugDosageText | CC BY-NC-ND | 33938158 | 20,343,958 | 2021-08 |
What was the outcome of reaction 'Acute myocardial infarction'? | Sipuleucel-T associated inflammatory cardiomyopathy: a case report and observations from a large pharmacovigilance database.
The major cardiovascular (CV) adverse effects observed with sipuleucel-T from large multi-institutional clinical trials included thromboembolic events, myocardial infarction, and congestive heart... | Recovering | ReactionOutcome | CC BY-NC-ND | 33938158 | 20,343,958 | 2021-08 |
What was the outcome of reaction 'Atrial fibrillation'? | Sipuleucel-T associated inflammatory cardiomyopathy: a case report and observations from a large pharmacovigilance database.
The major cardiovascular (CV) adverse effects observed with sipuleucel-T from large multi-institutional clinical trials included thromboembolic events, myocardial infarction, and congestive heart... | Recovering | ReactionOutcome | CC BY-NC-ND | 33938158 | 20,343,958 | 2021-08 |
What was the outcome of reaction 'Cardiac failure acute'? | Sipuleucel-T associated inflammatory cardiomyopathy: a case report and observations from a large pharmacovigilance database.
The major cardiovascular (CV) adverse effects observed with sipuleucel-T from large multi-institutional clinical trials included thromboembolic events, myocardial infarction, and congestive heart... | Recovering | ReactionOutcome | CC BY-NC-ND | 33938158 | 20,343,958 | 2021-08 |
What was the outcome of reaction 'Cardiac failure'? | Sipuleucel-T associated inflammatory cardiomyopathy: a case report and observations from a large pharmacovigilance database.
The major cardiovascular (CV) adverse effects observed with sipuleucel-T from large multi-institutional clinical trials included thromboembolic events, myocardial infarction, and congestive heart... | Recovering | ReactionOutcome | CC BY-NC-ND | 33938158 | 20,343,958 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Central nervous system lesion'. | ALK-positive lung cancer in a patient with recurrent brain metastases and meningeal dissemination who achieved long-term survival of more than seven years with sequential treatment of five ALK-inhibitors: A case report.
The incidence of central nervous system (CNS) metastases in patients with anaplastic lymphoma kinase... | BRIGATINIB | DrugsGivenReaction | CC BY-NC-ND | 33939293 | 19,267,991 | 2021-06 |
What was the outcome of reaction 'Central nervous system lesion'? | ALK-positive lung cancer in a patient with recurrent brain metastases and meningeal dissemination who achieved long-term survival of more than seven years with sequential treatment of five ALK-inhibitors: A case report.
The incidence of central nervous system (CNS) metastases in patients with anaplastic lymphoma kinase... | Recovering | ReactionOutcome | CC BY-NC-ND | 33939293 | 19,267,991 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Colitis'. | CD8-positive peripheral T cell lymphoma in a patient following long-term nivolumab for advanced lung adenocarcinoma: A case report.
A 54-year-old male smoker presented with hemoptysis. Advanced lung adenocarcinoma, cT1cN3M1b, stage IVB, was diagnosed. Enlargement of multiple intraperitoneal and inguinal lymph nodes and... | AMBROXOL HYDROCHLORIDE, CARBAZOCHROME SODIUM SULFONATE, CARBOCYSTEINE, DEXTROMETHORPHAN HYDROBROMIDE, NIVOLUMAB, RISEDRONATE SODIUM, SULFAMETHOXAZOLE\TRIMETHOPRIM, VONOPRAZAN FUMARATE | DrugsGivenReaction | CC BY | 33939308 | 18,188,225 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | CD8-positive peripheral T cell lymphoma in a patient following long-term nivolumab for advanced lung adenocarcinoma: A case report.
A 54-year-old male smoker presented with hemoptysis. Advanced lung adenocarcinoma, cT1cN3M1b, stage IVB, was diagnosed. Enlargement of multiple intraperitoneal and inguinal lymph nodes and... | CISPLATIN, CYCLOPHOSPHAMIDE, DOXORUBICIN, NIVOLUMAB, PEMETREXED, PREDNISOLONE, VINCRISTINE SULFATE, WARFARIN | DrugsGivenReaction | CC BY | 33939308 | 20,224,037 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Immune-mediated enterocolitis'. | CD8-positive peripheral T cell lymphoma in a patient following long-term nivolumab for advanced lung adenocarcinoma: A case report.
A 54-year-old male smoker presented with hemoptysis. Advanced lung adenocarcinoma, cT1cN3M1b, stage IVB, was diagnosed. Enlargement of multiple intraperitoneal and inguinal lymph nodes and... | CISPLATIN, CYCLOPHOSPHAMIDE, DOXORUBICIN, NIVOLUMAB, PEMETREXED, PREDNISOLONE, VINCRISTINE SULFATE, WARFARIN | DrugsGivenReaction | CC BY | 33939308 | 20,224,037 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | CD8-positive peripheral T cell lymphoma in a patient following long-term nivolumab for advanced lung adenocarcinoma: A case report.
A 54-year-old male smoker presented with hemoptysis. Advanced lung adenocarcinoma, cT1cN3M1b, stage IVB, was diagnosed. Enlargement of multiple intraperitoneal and inguinal lymph nodes and... | CISPLATIN, CYCLOPHOSPHAMIDE, DOXORUBICIN, NIVOLUMAB, PEMETREXED, PREDNISOLONE, VINCRISTINE SULFATE, WARFARIN | DrugsGivenReaction | CC BY | 33939308 | 20,197,841 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Peripheral T-cell lymphoma unspecified stage IV'. | CD8-positive peripheral T cell lymphoma in a patient following long-term nivolumab for advanced lung adenocarcinoma: A case report.
A 54-year-old male smoker presented with hemoptysis. Advanced lung adenocarcinoma, cT1cN3M1b, stage IVB, was diagnosed. Enlargement of multiple intraperitoneal and inguinal lymph nodes and... | CISPLATIN, CYCLOPHOSPHAMIDE, DOXORUBICIN, NIVOLUMAB, PEMETREXED, PREDNISOLONE, VINCRISTINE SULFATE, WARFARIN | DrugsGivenReaction | CC BY | 33939308 | 20,224,037 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Peripheral T-cell lymphoma unspecified'. | CD8-positive peripheral T cell lymphoma in a patient following long-term nivolumab for advanced lung adenocarcinoma: A case report.
A 54-year-old male smoker presented with hemoptysis. Advanced lung adenocarcinoma, cT1cN3M1b, stage IVB, was diagnosed. Enlargement of multiple intraperitoneal and inguinal lymph nodes and... | AMBROXOL HYDROCHLORIDE, CARBAZOCHROME SODIUM SULFONATE, CARBOCYSTEINE, DEXTROMETHORPHAN HYDROBROMIDE, NIVOLUMAB, RISEDRONATE SODIUM, SULFAMETHOXAZOLE\TRIMETHOPRIM, VONOPRAZAN FUMARATE | DrugsGivenReaction | CC BY | 33939308 | 18,188,225 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Therapy partial responder'. | CD8-positive peripheral T cell lymphoma in a patient following long-term nivolumab for advanced lung adenocarcinoma: A case report.
A 54-year-old male smoker presented with hemoptysis. Advanced lung adenocarcinoma, cT1cN3M1b, stage IVB, was diagnosed. Enlargement of multiple intraperitoneal and inguinal lymph nodes and... | CISPLATIN, CYCLOPHOSPHAMIDE, DOXORUBICIN, NIVOLUMAB, PEMETREXED, PREDNISOLONE, VINCRISTINE SULFATE, WARFARIN | DrugsGivenReaction | CC BY | 33939308 | 20,197,841 | 2021-06 |
What was the administration route of drug 'AMBROXOL HYDROCHLORIDE'? | CD8-positive peripheral T cell lymphoma in a patient following long-term nivolumab for advanced lung adenocarcinoma: A case report.
A 54-year-old male smoker presented with hemoptysis. Advanced lung adenocarcinoma, cT1cN3M1b, stage IVB, was diagnosed. Enlargement of multiple intraperitoneal and inguinal lymph nodes and... | Oral | DrugAdministrationRoute | CC BY | 33939308 | 18,188,225 | 2021-06 |
What was the administration route of drug 'CARBAZOCHROME SODIUM SULFONATE'? | CD8-positive peripheral T cell lymphoma in a patient following long-term nivolumab for advanced lung adenocarcinoma: A case report.
A 54-year-old male smoker presented with hemoptysis. Advanced lung adenocarcinoma, cT1cN3M1b, stage IVB, was diagnosed. Enlargement of multiple intraperitoneal and inguinal lymph nodes and... | Oral | DrugAdministrationRoute | CC BY | 33939308 | 18,188,225 | 2021-06 |
What was the administration route of drug 'CARBOCYSTEINE'? | CD8-positive peripheral T cell lymphoma in a patient following long-term nivolumab for advanced lung adenocarcinoma: A case report.
A 54-year-old male smoker presented with hemoptysis. Advanced lung adenocarcinoma, cT1cN3M1b, stage IVB, was diagnosed. Enlargement of multiple intraperitoneal and inguinal lymph nodes and... | Oral | DrugAdministrationRoute | CC BY | 33939308 | 18,188,225 | 2021-06 |
What was the administration route of drug 'DEXTROMETHORPHAN HYDROBROMIDE'? | CD8-positive peripheral T cell lymphoma in a patient following long-term nivolumab for advanced lung adenocarcinoma: A case report.
A 54-year-old male smoker presented with hemoptysis. Advanced lung adenocarcinoma, cT1cN3M1b, stage IVB, was diagnosed. Enlargement of multiple intraperitoneal and inguinal lymph nodes and... | Oral | DrugAdministrationRoute | CC BY | 33939308 | 18,188,225 | 2021-06 |
What was the administration route of drug 'NIVOLUMAB'? | CD8-positive peripheral T cell lymphoma in a patient following long-term nivolumab for advanced lung adenocarcinoma: A case report.
A 54-year-old male smoker presented with hemoptysis. Advanced lung adenocarcinoma, cT1cN3M1b, stage IVB, was diagnosed. Enlargement of multiple intraperitoneal and inguinal lymph nodes and... | Intravenous drip | DrugAdministrationRoute | CC BY | 33939308 | 18,188,225 | 2021-06 |
What was the administration route of drug 'RISEDRONATE SODIUM'? | CD8-positive peripheral T cell lymphoma in a patient following long-term nivolumab for advanced lung adenocarcinoma: A case report.
A 54-year-old male smoker presented with hemoptysis. Advanced lung adenocarcinoma, cT1cN3M1b, stage IVB, was diagnosed. Enlargement of multiple intraperitoneal and inguinal lymph nodes and... | Oral | DrugAdministrationRoute | CC BY | 33939308 | 18,188,225 | 2021-06 |
What was the administration route of drug 'SULFAMETHOXAZOLE\TRIMETHOPRIM'? | CD8-positive peripheral T cell lymphoma in a patient following long-term nivolumab for advanced lung adenocarcinoma: A case report.
A 54-year-old male smoker presented with hemoptysis. Advanced lung adenocarcinoma, cT1cN3M1b, stage IVB, was diagnosed. Enlargement of multiple intraperitoneal and inguinal lymph nodes and... | Oral | DrugAdministrationRoute | CC BY | 33939308 | 18,188,225 | 2021-06 |
What was the administration route of drug 'VONOPRAZAN FUMARATE'? | CD8-positive peripheral T cell lymphoma in a patient following long-term nivolumab for advanced lung adenocarcinoma: A case report.
A 54-year-old male smoker presented with hemoptysis. Advanced lung adenocarcinoma, cT1cN3M1b, stage IVB, was diagnosed. Enlargement of multiple intraperitoneal and inguinal lymph nodes and... | Oral | DrugAdministrationRoute | CC BY | 33939308 | 18,188,225 | 2021-06 |
What was the dosage of drug 'AMBROXOL HYDROCHLORIDE'? | CD8-positive peripheral T cell lymphoma in a patient following long-term nivolumab for advanced lung adenocarcinoma: A case report.
A 54-year-old male smoker presented with hemoptysis. Advanced lung adenocarcinoma, cT1cN3M1b, stage IVB, was diagnosed. Enlargement of multiple intraperitoneal and inguinal lymph nodes and... | 45 MILLIGRAM, QD | DrugDosageText | CC BY | 33939308 | 18,188,225 | 2021-06 |
What was the dosage of drug 'CARBAZOCHROME SODIUM SULFONATE'? | CD8-positive peripheral T cell lymphoma in a patient following long-term nivolumab for advanced lung adenocarcinoma: A case report.
A 54-year-old male smoker presented with hemoptysis. Advanced lung adenocarcinoma, cT1cN3M1b, stage IVB, was diagnosed. Enlargement of multiple intraperitoneal and inguinal lymph nodes and... | 30 MILLIGRAM, Q8H | DrugDosageText | CC BY | 33939308 | 18,188,225 | 2021-06 |
What was the dosage of drug 'CARBOCYSTEINE'? | CD8-positive peripheral T cell lymphoma in a patient following long-term nivolumab for advanced lung adenocarcinoma: A case report.
A 54-year-old male smoker presented with hemoptysis. Advanced lung adenocarcinoma, cT1cN3M1b, stage IVB, was diagnosed. Enlargement of multiple intraperitoneal and inguinal lymph nodes and... | 500 MILLIGRAM, Q8H | DrugDosageText | CC BY | 33939308 | 18,188,225 | 2021-06 |
What was the dosage of drug 'DEXTROMETHORPHAN HYDROBROMIDE'? | CD8-positive peripheral T cell lymphoma in a patient following long-term nivolumab for advanced lung adenocarcinoma: A case report.
A 54-year-old male smoker presented with hemoptysis. Advanced lung adenocarcinoma, cT1cN3M1b, stage IVB, was diagnosed. Enlargement of multiple intraperitoneal and inguinal lymph nodes and... | 15 MILLIGRAM, Q8H | DrugDosageText | CC BY | 33939308 | 18,188,225 | 2021-06 |
What was the dosage of drug 'RISEDRONATE SODIUM'? | CD8-positive peripheral T cell lymphoma in a patient following long-term nivolumab for advanced lung adenocarcinoma: A case report.
A 54-year-old male smoker presented with hemoptysis. Advanced lung adenocarcinoma, cT1cN3M1b, stage IVB, was diagnosed. Enlargement of multiple intraperitoneal and inguinal lymph nodes and... | 1 DOSAGE FORM, QWK (JELLY) | DrugDosageText | CC BY | 33939308 | 18,188,225 | 2021-06 |
What was the dosage of drug 'SULFAMETHOXAZOLE\TRIMETHOPRIM'? | CD8-positive peripheral T cell lymphoma in a patient following long-term nivolumab for advanced lung adenocarcinoma: A case report.
A 54-year-old male smoker presented with hemoptysis. Advanced lung adenocarcinoma, cT1cN3M1b, stage IVB, was diagnosed. Enlargement of multiple intraperitoneal and inguinal lymph nodes and... | 1 DOSAGE FORM, Q56H | DrugDosageText | CC BY | 33939308 | 18,188,225 | 2021-06 |
What was the dosage of drug 'VONOPRAZAN FUMARATE'? | CD8-positive peripheral T cell lymphoma in a patient following long-term nivolumab for advanced lung adenocarcinoma: A case report.
A 54-year-old male smoker presented with hemoptysis. Advanced lung adenocarcinoma, cT1cN3M1b, stage IVB, was diagnosed. Enlargement of multiple intraperitoneal and inguinal lymph nodes and... | 10 MILLIGRAM, QD | DrugDosageText | CC BY | 33939308 | 18,188,225 | 2021-06 |
What was the outcome of reaction 'Colitis'? | CD8-positive peripheral T cell lymphoma in a patient following long-term nivolumab for advanced lung adenocarcinoma: A case report.
A 54-year-old male smoker presented with hemoptysis. Advanced lung adenocarcinoma, cT1cN3M1b, stage IVB, was diagnosed. Enlargement of multiple intraperitoneal and inguinal lymph nodes and... | Recovered | ReactionOutcome | CC BY | 33939308 | 18,188,225 | 2021-06 |
What was the outcome of reaction 'Drug ineffective'? | CD8-positive peripheral T cell lymphoma in a patient following long-term nivolumab for advanced lung adenocarcinoma: A case report.
A 54-year-old male smoker presented with hemoptysis. Advanced lung adenocarcinoma, cT1cN3M1b, stage IVB, was diagnosed. Enlargement of multiple intraperitoneal and inguinal lymph nodes and... | Fatal | ReactionOutcome | CC BY | 33939308 | 20,197,841 | 2021-06 |
What was the outcome of reaction 'Immune-mediated enterocolitis'? | CD8-positive peripheral T cell lymphoma in a patient following long-term nivolumab for advanced lung adenocarcinoma: A case report.
A 54-year-old male smoker presented with hemoptysis. Advanced lung adenocarcinoma, cT1cN3M1b, stage IVB, was diagnosed. Enlargement of multiple intraperitoneal and inguinal lymph nodes and... | Recovered | ReactionOutcome | CC BY | 33939308 | 20,224,037 | 2021-06 |
What was the outcome of reaction 'Peripheral T-cell lymphoma unspecified stage IV'? | CD8-positive peripheral T cell lymphoma in a patient following long-term nivolumab for advanced lung adenocarcinoma: A case report.
A 54-year-old male smoker presented with hemoptysis. Advanced lung adenocarcinoma, cT1cN3M1b, stage IVB, was diagnosed. Enlargement of multiple intraperitoneal and inguinal lymph nodes and... | Fatal | ReactionOutcome | CC BY | 33939308 | 20,224,037 | 2021-06 |
What was the outcome of reaction 'Peripheral T-cell lymphoma unspecified'? | CD8-positive peripheral T cell lymphoma in a patient following long-term nivolumab for advanced lung adenocarcinoma: A case report.
A 54-year-old male smoker presented with hemoptysis. Advanced lung adenocarcinoma, cT1cN3M1b, stage IVB, was diagnosed. Enlargement of multiple intraperitoneal and inguinal lymph nodes and... | Fatal | ReactionOutcome | CC BY | 33939308 | 18,188,225 | 2021-06 |
What was the outcome of reaction 'Condition aggravated'? | Glasgow prognostic score for prediction of chemotherapy-triggered acute exacerbation interstitial lung disease in patients with small cell lung cancer.
Predicting the incidence of chemotherapy-triggered acute exacerbation of interstitial lung disease (AE-ILD) in patients with lung cancer is important because AE-ILD con... | Fatal | ReactionOutcome | CC BY | 33939332 | 19,548,591 | 2021-06 |
What was the outcome of reaction 'Interstitial lung disease'? | Glasgow prognostic score for prediction of chemotherapy-triggered acute exacerbation interstitial lung disease in patients with small cell lung cancer.
Predicting the incidence of chemotherapy-triggered acute exacerbation of interstitial lung disease (AE-ILD) in patients with lung cancer is important because AE-ILD con... | Fatal | ReactionOutcome | CC BY | 33939332 | 19,599,345 | 2021-06 |
What was the administration route of drug 'RIVAROXABAN'? | The development and validation of a multivariable model to predict the bleeding risk score for patients with non-valvular atrial fibrillation using direct oral anticoagulants in the Arab population.
Frequently used models, such as the HAS-BLED, ATRIA, ORBIT, and GARFIELD-AF evaluate the risk of bleeding when using an a... | Oral | DrugAdministrationRoute | CC BY | 33939729 | 19,315,818 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Disease progression'. | Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non-Small Cell Lung Cancer.
Epidermal growth factor receptor kinase domain duplication (EGFR-KDD) is a rare and poorly understood oncogenic mutation in non-small cell lung cancer (NSCLC). We aimed to investigate the acquired resistance mech... | ERLOTINIB | DrugsGivenReaction | CC BY-NC | 33940786 | 20,869,560 | 2021-05-03 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug resistance'. | Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non-Small Cell Lung Cancer.
Epidermal growth factor receptor kinase domain duplication (EGFR-KDD) is a rare and poorly understood oncogenic mutation in non-small cell lung cancer (NSCLC). We aimed to investigate the acquired resistance mech... | ERLOTINIB | DrugsGivenReaction | CC BY-NC | 33940786 | 20,880,166 | 2021-05-03 |
What was the dosage of drug 'ERLOTINIB'? | Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non-Small Cell Lung Cancer.
Epidermal growth factor receptor kinase domain duplication (EGFR-KDD) is a rare and poorly understood oncogenic mutation in non-small cell lung cancer (NSCLC). We aimed to investigate the acquired resistance mech... | UNK, 8 MONTHS | DrugDosageText | CC BY-NC | 33940786 | 20,869,560 | 2021-05-03 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Adverse drug reaction'. | Prognostic impact of additive chemotherapy after curative resection of metachronous colorectal liver metastasis: a single-centre retrospective study.
BACKGROUND
A prognostic benefit of additive chemotherapy in patients following resection of metachronous colorectal liver metastases (CRLM) remains controversial. Therefo... | FLUOROURACIL, PANITUMUMAB | DrugsGivenReaction | CC BY | 33941104 | 19,357,281 | 2021-05-03 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Colorectal cancer recurrent'. | Prognostic impact of additive chemotherapy after curative resection of metachronous colorectal liver metastasis: a single-centre retrospective study.
BACKGROUND
A prognostic benefit of additive chemotherapy in patients following resection of metachronous colorectal liver metastases (CRLM) remains controversial. Therefo... | FLUOROURACIL, PANITUMUMAB | DrugsGivenReaction | CC BY | 33941104 | 19,357,281 | 2021-05-03 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Death'. | Prognostic impact of additive chemotherapy after curative resection of metachronous colorectal liver metastasis: a single-centre retrospective study.
BACKGROUND
A prognostic benefit of additive chemotherapy in patients following resection of metachronous colorectal liver metastases (CRLM) remains controversial. Therefo... | FLUOROURACIL, PANITUMUMAB | DrugsGivenReaction | CC BY | 33941104 | 19,357,281 | 2021-05-03 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Metastases to liver'. | Prognostic impact of additive chemotherapy after curative resection of metachronous colorectal liver metastasis: a single-centre retrospective study.
BACKGROUND
A prognostic benefit of additive chemotherapy in patients following resection of metachronous colorectal liver metastases (CRLM) remains controversial. Therefo... | FLUOROURACIL, PANITUMUMAB | DrugsGivenReaction | CC BY | 33941104 | 19,357,281 | 2021-05-03 |
What was the outcome of reaction 'Death'? | Prognostic impact of additive chemotherapy after curative resection of metachronous colorectal liver metastasis: a single-centre retrospective study.
BACKGROUND
A prognostic benefit of additive chemotherapy in patients following resection of metachronous colorectal liver metastases (CRLM) remains controversial. Therefo... | Fatal | ReactionOutcome | CC BY | 33941104 | 19,357,281 | 2021-05-03 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Condition aggravated'. | Neutropenic enterocolitis-induced sepsis and disseminated intravascular coagulation after chemotherapy: a case report.
Neutropenic enterocolitis (NE) is a potentially life-threatening disease that primarily occurs in cancer patients treated with chemotherapy. NE has substantial morbidity and mortality, and its incidenc... | CARBOPLATIN, PACLITAXEL | DrugsGivenReaction | CC BY | 33941182 | 19,294,578 | 2021-05-03 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Disseminated intravascular coagulation'. | Neutropenic enterocolitis-induced sepsis and disseminated intravascular coagulation after chemotherapy: a case report.
Neutropenic enterocolitis (NE) is a potentially life-threatening disease that primarily occurs in cancer patients treated with chemotherapy. NE has substantial morbidity and mortality, and its incidenc... | CARBOPLATIN, PACLITAXEL | DrugsGivenReaction | CC BY | 33941182 | 19,329,907 | 2021-05-03 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Febrile neutropenia'. | Neutropenic enterocolitis-induced sepsis and disseminated intravascular coagulation after chemotherapy: a case report.
Neutropenic enterocolitis (NE) is a potentially life-threatening disease that primarily occurs in cancer patients treated with chemotherapy. NE has substantial morbidity and mortality, and its incidenc... | CARBOPLATIN, PACLITAXEL | DrugsGivenReaction | CC BY | 33941182 | 19,329,907 | 2021-05-03 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Neutropenic colitis'. | Neutropenic enterocolitis-induced sepsis and disseminated intravascular coagulation after chemotherapy: a case report.
Neutropenic enterocolitis (NE) is a potentially life-threatening disease that primarily occurs in cancer patients treated with chemotherapy. NE has substantial morbidity and mortality, and its incidenc... | CARBOPLATIN, PACLITAXEL | DrugsGivenReaction | CC BY | 33941182 | 19,329,907 | 2021-05-03 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Product use in unapproved indication'. | Neutropenic enterocolitis-induced sepsis and disseminated intravascular coagulation after chemotherapy: a case report.
Neutropenic enterocolitis (NE) is a potentially life-threatening disease that primarily occurs in cancer patients treated with chemotherapy. NE has substantial morbidity and mortality, and its incidenc... | CARBOPLATIN, PACLITAXEL | DrugsGivenReaction | CC BY | 33941182 | 19,845,450 | 2021-05-03 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Sepsis'. | Neutropenic enterocolitis-induced sepsis and disseminated intravascular coagulation after chemotherapy: a case report.
Neutropenic enterocolitis (NE) is a potentially life-threatening disease that primarily occurs in cancer patients treated with chemotherapy. NE has substantial morbidity and mortality, and its incidenc... | CARBOPLATIN, PACLITAXEL | DrugsGivenReaction | CC BY | 33941182 | 19,294,578 | 2021-05-03 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Septic shock'. | Neutropenic enterocolitis-induced sepsis and disseminated intravascular coagulation after chemotherapy: a case report.
Neutropenic enterocolitis (NE) is a potentially life-threatening disease that primarily occurs in cancer patients treated with chemotherapy. NE has substantial morbidity and mortality, and its incidenc... | CARBOPLATIN, PACLITAXEL | DrugsGivenReaction | CC BY | 33941182 | 19,329,907 | 2021-05-03 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Systemic inflammatory response syndrome'. | Neutropenic enterocolitis-induced sepsis and disseminated intravascular coagulation after chemotherapy: a case report.
Neutropenic enterocolitis (NE) is a potentially life-threatening disease that primarily occurs in cancer patients treated with chemotherapy. NE has substantial morbidity and mortality, and its incidenc... | CARBOPLATIN, PACLITAXEL | DrugsGivenReaction | CC BY | 33941182 | 19,329,907 | 2021-05-03 |
What was the outcome of reaction 'Condition aggravated'? | Neutropenic enterocolitis-induced sepsis and disseminated intravascular coagulation after chemotherapy: a case report.
Neutropenic enterocolitis (NE) is a potentially life-threatening disease that primarily occurs in cancer patients treated with chemotherapy. NE has substantial morbidity and mortality, and its incidenc... | Recovered | ReactionOutcome | CC BY | 33941182 | 19,294,578 | 2021-05-03 |
What was the outcome of reaction 'Disseminated intravascular coagulation'? | Neutropenic enterocolitis-induced sepsis and disseminated intravascular coagulation after chemotherapy: a case report.
Neutropenic enterocolitis (NE) is a potentially life-threatening disease that primarily occurs in cancer patients treated with chemotherapy. NE has substantial morbidity and mortality, and its incidenc... | Recovered | ReactionOutcome | CC BY | 33941182 | 19,329,907 | 2021-05-03 |
What was the outcome of reaction 'Febrile neutropenia'? | Neutropenic enterocolitis-induced sepsis and disseminated intravascular coagulation after chemotherapy: a case report.
Neutropenic enterocolitis (NE) is a potentially life-threatening disease that primarily occurs in cancer patients treated with chemotherapy. NE has substantial morbidity and mortality, and its incidenc... | Recovered | ReactionOutcome | CC BY | 33941182 | 19,329,907 | 2021-05-03 |
What was the outcome of reaction 'Neutropenic colitis'? | Neutropenic enterocolitis-induced sepsis and disseminated intravascular coagulation after chemotherapy: a case report.
Neutropenic enterocolitis (NE) is a potentially life-threatening disease that primarily occurs in cancer patients treated with chemotherapy. NE has substantial morbidity and mortality, and its incidenc... | Recovered | ReactionOutcome | CC BY | 33941182 | 19,329,907 | 2021-05-03 |
What was the outcome of reaction 'Sepsis'? | Neutropenic enterocolitis-induced sepsis and disseminated intravascular coagulation after chemotherapy: a case report.
Neutropenic enterocolitis (NE) is a potentially life-threatening disease that primarily occurs in cancer patients treated with chemotherapy. NE has substantial morbidity and mortality, and its incidenc... | Recovered | ReactionOutcome | CC BY | 33941182 | 19,294,578 | 2021-05-03 |
What was the outcome of reaction 'Septic shock'? | Neutropenic enterocolitis-induced sepsis and disseminated intravascular coagulation after chemotherapy: a case report.
Neutropenic enterocolitis (NE) is a potentially life-threatening disease that primarily occurs in cancer patients treated with chemotherapy. NE has substantial morbidity and mortality, and its incidenc... | Recovered | ReactionOutcome | CC BY | 33941182 | 19,329,907 | 2021-05-03 |
What was the outcome of reaction 'Systemic inflammatory response syndrome'? | Neutropenic enterocolitis-induced sepsis and disseminated intravascular coagulation after chemotherapy: a case report.
Neutropenic enterocolitis (NE) is a potentially life-threatening disease that primarily occurs in cancer patients treated with chemotherapy. NE has substantial morbidity and mortality, and its incidenc... | Recovered | ReactionOutcome | CC BY | 33941182 | 19,329,907 | 2021-05-03 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Molecular Analysis of the Kidney From a Patient With COVID-19-Associated Collapsing Glomerulopathy.
Recent case reports suggest that coronavirus disease 2019 (COVID-19) is associated with collapsing glomerulopathy in African Americans with apolipoprotein L1 gene (APOL1) risk alleles; however, it is unclear whether dise... | APIXABAN, HYDROXYCHLOROQUINE | DrugsGivenReaction | CC BY-NC-ND | 33942030 | 20,316,936 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Acute lymphocytic leukaemia'. | Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry.
Data on clinical use of ponatinib are limited. This prospective registry aimed to evaluate outcomes of ponatinib treatment in routine practice over 3 years (2016... | PONATINIB | DrugsGivenReaction | CC BY | 33942128 | 20,255,545 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Chronic myeloid leukaemia'. | Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry.
Data on clinical use of ponatinib are limited. This prospective registry aimed to evaluate outcomes of ponatinib treatment in routine practice over 3 years (2016... | PONATINIB | DrugsGivenReaction | CC BY | 33942128 | 20,255,401 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug intolerance'. | Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry.
Data on clinical use of ponatinib are limited. This prospective registry aimed to evaluate outcomes of ponatinib treatment in routine practice over 3 years (2016... | PONATINIB | DrugsGivenReaction | CC BY | 33942128 | 20,258,331 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Chronic inflammatory demyelinating polyradiculoneuropathy'. | Pembrolizumab-caused polyradiculoneuropathy as an immune-related adverse event.
Immune-related adverse events (irAEs) commonly involve the gastrointestinal tract, endocrine glands, skin, and liver, and rarely the nervous system. The pathomechanism of irAEs in the nervous system is unclear, and so characterizing these s... | PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 33942396 | 19,357,891 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Colitis'. | Pembrolizumab-caused polyradiculoneuropathy as an immune-related adverse event.
Immune-related adverse events (irAEs) commonly involve the gastrointestinal tract, endocrine glands, skin, and liver, and rarely the nervous system. The pathomechanism of irAEs in the nervous system is unclear, and so characterizing these s... | CISPLATIN, DOXORUBICIN, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 33942396 | 20,223,911 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Pembrolizumab-caused polyradiculoneuropathy as an immune-related adverse event.
Immune-related adverse events (irAEs) commonly involve the gastrointestinal tract, endocrine glands, skin, and liver, and rarely the nervous system. The pathomechanism of irAEs in the nervous system is unclear, and so characterizing these s... | CISPLATIN, DOXORUBICIN, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 33942396 | 20,223,911 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Guillain-Barre syndrome'. | Pembrolizumab-caused polyradiculoneuropathy as an immune-related adverse event.
Immune-related adverse events (irAEs) commonly involve the gastrointestinal tract, endocrine glands, skin, and liver, and rarely the nervous system. The pathomechanism of irAEs in the nervous system is unclear, and so characterizing these s... | CISPLATIN, DOXORUBICIN, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 33942396 | 20,223,911 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Immune-mediated enterocolitis'. | Pembrolizumab-caused polyradiculoneuropathy as an immune-related adverse event.
Immune-related adverse events (irAEs) commonly involve the gastrointestinal tract, endocrine glands, skin, and liver, and rarely the nervous system. The pathomechanism of irAEs in the nervous system is unclear, and so characterizing these s... | PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 33942396 | 19,357,891 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Intestinal perforation'. | Pembrolizumab-caused polyradiculoneuropathy as an immune-related adverse event.
Immune-related adverse events (irAEs) commonly involve the gastrointestinal tract, endocrine glands, skin, and liver, and rarely the nervous system. The pathomechanism of irAEs in the nervous system is unclear, and so characterizing these s... | CISPLATIN, DOXORUBICIN, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 33942396 | 20,223,911 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Polyneuropathy in malignant disease'. | Pembrolizumab-caused polyradiculoneuropathy as an immune-related adverse event.
Immune-related adverse events (irAEs) commonly involve the gastrointestinal tract, endocrine glands, skin, and liver, and rarely the nervous system. The pathomechanism of irAEs in the nervous system is unclear, and so characterizing these s... | CISPLATIN, DOXORUBICIN, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 33942396 | 20,223,911 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective for unapproved indication'. | Bi-allelic KARS1 pathogenic variants affecting functions of cytosolic and mitochondrial isoforms are associated with a progressive and multisystem disease.
KARS1 encodes a lysyl-transfer RNA synthetase (LysRS) that links lysine to its cognate transfer RNA. Two different KARS1 isoforms exert functional effects in cytoso... | LEVETIRACETAM, PHENOBARBITAL, TOPIRAMATE, VIGABATRIN | DrugsGivenReaction | CC BY | 33942428 | 20,174,942 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Bi-allelic KARS1 pathogenic variants affecting functions of cytosolic and mitochondrial isoforms are associated with a progressive and multisystem disease.
KARS1 encodes a lysyl-transfer RNA synthetase (LysRS) that links lysine to its cognate transfer RNA. Two different KARS1 isoforms exert functional effects in cytoso... | LEVETIRACETAM, PHENOBARBITAL, TOPIRAMATE, VIGABATRIN | DrugsGivenReaction | CC BY | 33942428 | 20,174,942 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Therapy non-responder'. | Bi-allelic KARS1 pathogenic variants affecting functions of cytosolic and mitochondrial isoforms are associated with a progressive and multisystem disease.
KARS1 encodes a lysyl-transfer RNA synthetase (LysRS) that links lysine to its cognate transfer RNA. Two different KARS1 isoforms exert functional effects in cytoso... | LEVETIRACETAM, PHENOBARBITAL, TOPIRAMATE, VIGABATRIN | DrugsGivenReaction | CC BY | 33942428 | 20,191,988 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Limited effect of afatinib in a non-small cell lung cancer patient harboring an epidermal growth factor receptor K860I missense mutation: A case report.
Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are key drugs in the treatment of non-small cell lung cancer (NSCLC) patients with EGFR mutat... | AFATINIB | DrugsGivenReaction | CC BY | 33942527 | 19,260,944 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Intestinal perforation'. | Limited effect of afatinib in a non-small cell lung cancer patient harboring an epidermal growth factor receptor K860I missense mutation: A case report.
Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are key drugs in the treatment of non-small cell lung cancer (NSCLC) patients with EGFR mutat... | BEVACIZUMAB, CISPLATIN, PEMETREXED | DrugsGivenReaction | CC BY | 33942527 | 20,211,484 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Lung neoplasm'. | Limited effect of afatinib in a non-small cell lung cancer patient harboring an epidermal growth factor receptor K860I missense mutation: A case report.
Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are key drugs in the treatment of non-small cell lung cancer (NSCLC) patients with EGFR mutat... | AFATINIB | DrugsGivenReaction | CC BY | 33942527 | 19,260,944 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Metastases to central nervous system'. | Limited effect of afatinib in a non-small cell lung cancer patient harboring an epidermal growth factor receptor K860I missense mutation: A case report.
Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are key drugs in the treatment of non-small cell lung cancer (NSCLC) patients with EGFR mutat... | AFATINIB | DrugsGivenReaction | CC BY | 33942527 | 19,260,944 | 2021-06 |
What was the dosage of drug 'BEVACIZUMAB'? | Limited effect of afatinib in a non-small cell lung cancer patient harboring an epidermal growth factor receptor K860I missense mutation: A case report.
Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are key drugs in the treatment of non-small cell lung cancer (NSCLC) patients with EGFR mutat... | UNK, TWO CYCLES | DrugDosageText | CC BY | 33942527 | 20,211,484 | 2021-06 |
What was the dosage of drug 'CISPLATIN'? | Limited effect of afatinib in a non-small cell lung cancer patient harboring an epidermal growth factor receptor K860I missense mutation: A case report.
Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are key drugs in the treatment of non-small cell lung cancer (NSCLC) patients with EGFR mutat... | UNK, TWO CYCLES | DrugDosageText | CC BY | 33942527 | 20,211,484 | 2021-06 |
What was the dosage of drug 'PEMETREXED'? | Limited effect of afatinib in a non-small cell lung cancer patient harboring an epidermal growth factor receptor K860I missense mutation: A case report.
Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are key drugs in the treatment of non-small cell lung cancer (NSCLC) patients with EGFR mutat... | UNK, TWO CYCLES | DrugDosageText | CC BY | 33942527 | 20,211,484 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Toxic skin eruption'. | Pleomorphicskin eruptions in a COVID-19 affected patient: Case report and review of the literature.
The coronavirus disease (COVID-19), during its course, may involve several organs, including the skin with a petechial skin rash, urticaria and erythematous rash, or varicella-like eruption, representing an additional ef... | CEFTRIAXONE SODIUM, DARUNAVIR ETHANOLATE, ENOXAPARIN, FILGRASTIM, HYDROXYCHLOROQUINE SULFATE, OMEPRAZOLE, RITONAVIR, SARILUMAB | DrugsGivenReaction | CC BY | 33942541 | 19,426,155 | 2021-09 |
What was the administration route of drug 'OMEPRAZOLE'? | Pleomorphicskin eruptions in a COVID-19 affected patient: Case report and review of the literature.
The coronavirus disease (COVID-19), during its course, may involve several organs, including the skin with a petechial skin rash, urticaria and erythematous rash, or varicella-like eruption, representing an additional ef... | Oral | DrugAdministrationRoute | CC BY | 33942541 | 20,049,328 | 2021-09 |
What was the dosage of drug 'ENOXAPARIN SODIUM'? | Pleomorphicskin eruptions in a COVID-19 affected patient: Case report and review of the literature.
The coronavirus disease (COVID-19), during its course, may involve several organs, including the skin with a petechial skin rash, urticaria and erythematous rash, or varicella-like eruption, representing an additional ef... | 4000 INTERNATIONAL UNIT, BID | DrugDosageText | CC BY | 33942541 | 19,281,631 | 2021-09 |
What was the outcome of reaction 'Rash'? | Pleomorphicskin eruptions in a COVID-19 affected patient: Case report and review of the literature.
The coronavirus disease (COVID-19), during its course, may involve several organs, including the skin with a petechial skin rash, urticaria and erythematous rash, or varicella-like eruption, representing an additional ef... | Recovered | ReactionOutcome | CC BY | 33942541 | 20,049,328 | 2021-09 |
What was the outcome of reaction 'Toxic skin eruption'? | Pleomorphicskin eruptions in a COVID-19 affected patient: Case report and review of the literature.
The coronavirus disease (COVID-19), during its course, may involve several organs, including the skin with a petechial skin rash, urticaria and erythematous rash, or varicella-like eruption, representing an additional ef... | Recovered | ReactionOutcome | CC BY | 33942541 | 19,426,155 | 2021-09 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cytomegalovirus infection'. | Convalescent plasma, cytomegalovirus infection, and persistent leukopenia in COVID-19 recovery phase: What is the link?
Therapies used to tide over acute crisis of COVID-19 infection may lower the immunity, which can lead to secondary infection or a reactivation of latent infection. We report a 75-years-old male patien... | AZITHROMYCIN ANHYDROUS, COVID-19 CONVALESCENT PLASMA, HYDROXYCHLOROQUINE, METHYLPREDNISOLONE, REMDESIVIR | DrugsGivenReaction | CC BY-NC-SA | 33942774 | 19,523,651 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Disease progression'. | Convalescent plasma, cytomegalovirus infection, and persistent leukopenia in COVID-19 recovery phase: What is the link?
Therapies used to tide over acute crisis of COVID-19 infection may lower the immunity, which can lead to secondary infection or a reactivation of latent infection. We report a 75-years-old male patien... | AZITHROMYCIN ANHYDROUS, HYDROXYCHLOROQUINE, METHYLPREDNISOLONE | DrugsGivenReaction | CC BY-NC-SA | 33942774 | 19,585,139 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Leukopenia'. | Convalescent plasma, cytomegalovirus infection, and persistent leukopenia in COVID-19 recovery phase: What is the link?
Therapies used to tide over acute crisis of COVID-19 infection may lower the immunity, which can lead to secondary infection or a reactivation of latent infection. We report a 75-years-old male patien... | AZITHROMYCIN ANHYDROUS, COVID-19 CONVALESCENT PLASMA, HYDROXYCHLOROQUINE, METHYLPREDNISOLONE, REMDESIVIR | DrugsGivenReaction | CC BY-NC-SA | 33942774 | 19,523,651 | 2021 |
What was the outcome of reaction 'Cytomegalovirus infection'? | Convalescent plasma, cytomegalovirus infection, and persistent leukopenia in COVID-19 recovery phase: What is the link?
Therapies used to tide over acute crisis of COVID-19 infection may lower the immunity, which can lead to secondary infection or a reactivation of latent infection. We report a 75-years-old male patien... | Recovered | ReactionOutcome | CC BY-NC-SA | 33942774 | 19,523,651 | 2021 |
What was the outcome of reaction 'Leukopenia'? | Convalescent plasma, cytomegalovirus infection, and persistent leukopenia in COVID-19 recovery phase: What is the link?
Therapies used to tide over acute crisis of COVID-19 infection may lower the immunity, which can lead to secondary infection or a reactivation of latent infection. We report a 75-years-old male patien... | Recovered | ReactionOutcome | CC BY-NC-SA | 33942774 | 19,523,651 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Anti factor VIII antibody positive'. | Rehabilitation management of a triceps surae muscle injury in a young male with haemophilia A and high-titre inhibitors.
Haemophilia A is a rare inherited hematologic disorder characterized by a deficit of coagulation factor VIII. It is associated with frequent episodes of musculoskeletal bleedings that occur mainly in... | ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT | DrugsGivenReaction | CC BY-NC-SA | 33944815 | 19,545,241 | 2021-04-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Haemorrhage'. | Rehabilitation management of a triceps surae muscle injury in a young male with haemophilia A and high-titre inhibitors.
Haemophilia A is a rare inherited hematologic disorder characterized by a deficit of coagulation factor VIII. It is associated with frequent episodes of musculoskeletal bleedings that occur mainly in... | ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT | DrugsGivenReaction | CC BY-NC-SA | 33944815 | 19,605,906 | 2021-04-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Inhibiting antibodies'. | Rehabilitation management of a triceps surae muscle injury in a young male with haemophilia A and high-titre inhibitors.
Haemophilia A is a rare inherited hematologic disorder characterized by a deficit of coagulation factor VIII. It is associated with frequent episodes of musculoskeletal bleedings that occur mainly in... | ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT | DrugsGivenReaction | CC BY-NC-SA | 33944815 | 19,605,906 | 2021-04-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Treatment failure'. | Rehabilitation management of a triceps surae muscle injury in a young male with haemophilia A and high-titre inhibitors.
Haemophilia A is a rare inherited hematologic disorder characterized by a deficit of coagulation factor VIII. It is associated with frequent episodes of musculoskeletal bleedings that occur mainly in... | ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT | DrugsGivenReaction | CC BY-NC-SA | 33944815 | 19,605,906 | 2021-04-30 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.